Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients

Godfrey Wagutu,John GITAU,Kennedy Mwangi,Mary Murithi,Elias Melly,Alexandra R Harris,Shahin Sayed,Stefan Ambs,Francis Makokha

DOI: https://doi.org/10.1101/2024.06.18.24309133

2024-06-20

Abstract:Background: The immune response against tumors relies on distinguishing between self and non-self, the basis of cancer immunotherapy. Neoantigens from somatic mutations are central to many immunotherapeutic strategies and understanding their landscape in breast cancer is crucial for targeted interventions. We aimed to profile neoantigens in Kenyan breast cancer patients using genomic DNA and total RNA from paired tumor and adjacent non-cancerous tissue samples of 23 patients. Methods: We sequenced the genome-wide exome (WES) and RNA, from which somatic mutations were identified and their expression quantified, respectively. Neoantigen prediction focused on human leukocyte antigens (HLA) crucial to cancer, HLA type I. HLA alleles were predicted from WES data covering the adjacent non-cancerous tissue samples, identifying four alleles that were present in at least 50% of the patients. Neoantigens were deemed potentially immunogenic if their predicted median IC50 binding scores were ≤500nM and were expressed [transcripts per million (TPM) >1] in tumor samples. Results: An average of 1465 neoantigens covering 10260 genes had ≤500nM median IC50 binding score and >1 TPM in the 23 patients and their presence significantly correlated with the somatic mutations (R2 =0.570, P=0.001). Assessing 58 genes reported in the catalog of somatic mutations in cancer (COSMIC, v99) to be commonly mutated in breast cancer, 44 (76%) produced >2 neoantigens among the 23 patients, with a mean of 10.5 ranging from 2 to 93. For the 44 genes, a total of 477 putative neoantigens were identified, predominantly derived from missense mutations (88%), indels (6%), and frameshift mutations (6%). Notably, 78% of the putative breast cancer neoantigens were patient-specific. HLA-C*06:01 allele was associated with the majority of neoantigens (194), followed by HLA-A*30:01 (131), HLA-A*02:01 (103), and HLA-B*58:01 (49). Among the genes of interest that produced putative neoantigens were MUC17, TTN, MUC16, AKAP9, NEB, RP1L1, CDH23, PCDHB10, BRCA2, TP53, TG, and RB1. Conclusions: The unique neoantigen profiles in our patient group highlight the potential of immunotherapy in personalized breast cancer treatment as well as potential biomarkers for prognosis. The unique mutations producing these neoantigens, compared to other populations, provide an opportunity for validation in a much larger sample cohort.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: by analyzing the whole - exome sequencing (WES) and RNA sequencing data of breast cancer patients in Kenya, to reveal the unique neoantigen characteristics in these patients. Specifically, the research aims to:

1. **Determine the neoantigen profile**: By sequencing genomic DNA and total RNA from paired tumor tissues and adjacent non - cancerous tissue samples of 23 Kenyan breast cancer patients, identify and predict neoantigens.

2. **Evaluate the relationship between neoantigens and somatic mutations**: Investigate whether the number and nature of neoantigens are related to somatic mutations, especially those in commonly mutated genes in breast cancer.

3. **Explore the potential of personalized immunotherapy**: Evaluate whether these unique neoantigen profiles can provide potential targets for personalized immunotherapy and serve as prognostic biomarkers.

4. **Fill the data gap in specific populations**: Since data on neoantigens are scarce in sub - Saharan African countries such as Kenya, this study aims to fill this gap and provide a basis for future drug development and treatment strategies.

### Main methods and techniques

- **Sequencing techniques**: Use whole - exome sequencing (WES) and RNA sequencing to obtain genomic and transcriptomic data.
- **Variant detection**: Detect somatic mutations by tools such as MuTect2 and perform functional annotation using VEP.
- **HLA typing**: Use the HLA - HD tool to predict HLA - class I alleles from the WES data of normal samples.
- **Neoantigen prediction**: Use pVACseq combined with multiple algorithms (such as MHCflurry, MHCnuggetsI, SMM, SMMPMBEC) to predict neoantigens and screen out neoantigens with high affinity (IC50 ≤ 500nM) and relatively high expression levels (TPM > 1).

### Key findings

- **Number of neoantigens**: On average, each patient has 1,465 neoantigens, and their presence is significantly correlated with somatic mutations ($R^2 = 0.570, P = 0.001$).
- **Mutated genes**: Among 62 known breast cancer - mutated genes, 44 genes produce more than 2 neoantigens, 88% of which are from missense mutations.
- **HLA allele association**: The HLA - C*06:01 allele is associated with the largest number of neoantigens (194).
- **Patient - specificity**: 78% of neoantigens are patient - specific.

### Conclusion

This study reveals the unique neoantigen profiles in Kenyan breast cancer patients, emphasizes the potential of personalized immunotherapy, and provides a basis for further verification. At the same time, the research results also suggest that these findings need to be further verified in larger - scale cohorts to ensure their reliability and clinical application value.